

Suppression of Arthritis by Immunomodulatory Leaps Peptide Vaccines in Animal Models of Rheumatoid Arthritis

Adrienn Markovics^{1*}, Daniel H. Zimmerman², Katalin Mikecz¹, Ken S. Rosenthal³

¹Department of Orthopedic Surgery, Rush University Medical Center, 1735 W Harrison St, Chicago, IL 60612, USA

²CEL-SCI Corporation, 8229 Boone Blvd, Vienna, VA 22182, USA

³Department of Basic Medical Sciences, Augusta University/University of Georgia Medical Partnership, 1425 Prince Avenue, Athens, GA 30602, USA

*Correspondence to: Adrienn Markovics, Department of Orthopedic Surgery, Rush University Medical Center, 1735 W Harrison St, Chicago, IL 60612, USA, Tel: 13126612147; E-mail: Adrienn_Markovics@rush.edu

Received: September 19, 2021; Accepted: October 13, 2021; Published: October 18, 2021

Citation: Markovics A, Zimmerman D H, Mikecz K, Rosenthal KS(2021) Suppression of Arthritis by Immunomodulatory LEAPS Peptide Vaccines in Animal Models of Rheumatoid Arthritis. Int J Drug Dev & Res Vol: 13 No: 5

Abstract

This Commentary presents the background, summary, and conclusions of a recently published article on preclinical studies of disease suppression by immunomodulatory peptide vaccines in mouse models of rheumatoid arthritis (RA). RA represents one of the most common autoimmune diseases that severely impact the quality of life of patients and put huge burden on healthcare. Therapeutic options are available to treat RA, ranging from over-the-counter anti-inflammatory drugs to classical immunosuppressants and newer inhibitors of inflammatory cytokine pathways. Unfortunately, 30-50% of RA patients do not respond effectively to current treatments. Based on the guidelines of the European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR), once a diagnosis is established, therapy should start with a conventional synthetic disease-modifying anti-rheumatic drug (csDMARD) such as methotrexate or leflunomide. These drugs elicit general immune suppression but side effects are very common with extended use, and several drugs in this group are contraindicated during pregnancy. If adequate remission is not achieved by csDMARDs, a biologic DMARD (bDMARD) is the next option. bDMARDs include soluble cytokine receptors, receptor antagonists, and monoclonal antibodies against single cytokines, cytokine receptors, or other cell-surface molecules. These agents primarily act by neutralizing the action of a particular cytokine or a cell-surface receptor and as such, they are not disease-specific. Janus kinase (JAK) inhibitors represent a class of targeted synthetic DMARDs (tsDMARDs). JAK inhibitors act intracellularly and inhibit the downstream signaling of several pro-inflammatory cytokines. These therapies are not ideal because they are either limited to treating the symptoms or they ablate inflammatory pathways that are important for critical immune functions and hence suppress necessary responses that fight infections or prevent tumor development.

Keywords: peptide vaccine; immunotherapy; rheumatoid arthritis; animal models

of autoimmune conditions. Unlike conventional vaccines, which activate antimicrobial antibody and proinflammatory T-cell responses, therapeutic vaccines activate T-cell mediated responses that modulate ongoing pro-inflammatory pathogenic processes to suppress the disease-specific immunopathology [4]. The Ligand Epitope Antigen Presentation System (LEAPS) provides a platform to design antigen-specific therapeutic vaccines customized to modulate the pro-inflammatory response driving the disease. LEAPS vaccines consist of an immune cell-binding ligand (ICBL) attached through a triglycine linker to a peptide containing a T-cell epitope.

The J ICBL directs the immune response to elicit an interleukin (IL)-12 and interferon gamma (IFN γ) T helper 1 (Th1) cell driven response, whereas the DerG ICBL directs the vaccine to Th2 or regulatory (Treg) cells and elicits an antigen-specific IL-4 and IL-10 production [5,6]. Our recent study [1] demonstrated the therapeutic effect of two DerG-LEAPS vaccine formulations containing distinct cartilage proteoglycan (PG, aggrecan) epitopes, separately and in combination, on the G1 proteoglycan domain-induced arthritis (GIA) model of RA. The GIA model is established in aging female BALB/c mice, is driven by (Th1) pro-inflammatory responses and the resultant symptomatology and disease parameters closely resemble the human disease [2]. The first vaccine, DerG-PG70 (also referred to as CEL-4000, the DerG-PG peptide administered with adjuvant), contained the most immunogenic epitope of the G1 domain of PG, and was shown to suppress ongoing arthritis by down-modulating pro-inflammatory Th1 and Th17 immune responses in the GIA and proteoglycan-induced arthritis (PGIA) mouse models [7]. The other vaccine (DerG-PG275Cit) contains a citrullinated PG epitope which is immunogenic in mice with PGIA as well as in human RA patients [8].

In the most recent study [3], the efficacy of the two vaccines was compared by treating mice already exhibiting the disease symptoms of GIA. Each of the vaccines, separately, as well as in combination, reduced the severity of disease, as indicated by the visual arthritis scores, and also reduced tissue damage, as confirmed by histopathology, in comparison to control mice treated with adjuvant without LEAPS peptides. In order to determine how the vaccines modulated disease progression, we investigated their effects on intracellular anti-inflammatory and pro-inflammatory cytokine content as well as cytokine release of CD4⁺ spleen cells of the GIA mice. These cells from treated mice preferentially produced anti-inflammatory (IL-4 and IL-10) rather than proinflammatory

Introduction

Therapeutic vaccines represent a new approach to the treatment

anti-inflammatory (IL-4 and IL-10) rather than proinflammatory (IFN γ or IL-17) cytokines in culture. Similarly, cytokines secreted by CD4⁺ cells of unvaccinated GIA mice, but differentiated in vitro to Th2 cells and treated with either or both DerG vaccine peptides, exhibited an enhanced anti-inflammatory (IL-4, IL10) profile. These results indicate that the vaccines provide therapy by reinforcing beneficial anti-inflammatory cytokine responses rather than the pro-inflammatory responses. Although antibodies against vaccine components should not contribute to the therapeutic effect, analysis of the antibody response to the vaccines did indicate differences in the mode of action for CEL-4000 and DerG-PG275Cit. Whereas sera from CEL-4000 vaccinated mice contained antibodies to both the DerG and PG70 components of the vaccine, antibodies to neither peptide were detected in the sera of DerG-PG275Cit vaccinated mice. Serum antibodies from GIA mice in the combined vaccine treatment group resembled those from mice treated with CEL-4000 alone.

Conclusion

CEL-4000, DerG-PG275Cit and the combination of these peptides elicit an immunomodulatory therapy in mice with RA-like arthritis driven by pro-inflammatory Th1 responses. The combination of these DerG-LEAPS vaccines may provide greater epitope coverage and efficacy in RA patients than either vaccine alone. They join the J-LEAPS (CEL-2000) vaccine that is effective in treating collagen induced Th17-driven arthritis in mice (Figure 1). These peptide vaccines differ from other approaches to the treatment of RA in that LEAPS vaccines are antigen and cytokine response specific. They modulate the overall antigen-specific immune responses that drive the disease rather than nonspecifically ablate a single cytokine or cell type, or inhibit RA-unrelated inflammatory immune responses. LEAPS vaccines also provide the ability to customize therapy for a patient depending upon the antigen and the pro-inflammatory cytokine response driving the disease. Therefore, LEAPS vaccines have the potential to maximize therapy and minimize ablative immunosuppression.

Figure1: Schematic representation of the immune responses modulated by LEAPS therapeutic vaccines in animal models of rheumatoid arthritis (RA). CEL- 4000 and DerG-275Cit are DerG-LEAPS peptide conjugates containing different proteoglycan epitopes. These vaccines separately or in combination blocked disease progression in the pro-inflammatory T helper 1 cell-driven GIA model of RA. In an earlier study, a J-LEAPS vaccine containing a collagen II epitope, was therapeutic in the Th17-driven collagen-induced arthritis (CIA) model of RA [6].

References

- Zimmerman DH, Mikecz K, Markovics A, Carambula RE, Ciemielewski JC, Toth DM, et al. (2021) Vaccination by Two DerG LEAPS Conjugates Incorporating Distinct Proteoglycan (PG, Aggrecan) Epitopes Provides Therapy by Different Immune Mechanisms in a Mouse Model of Rheumatoid Arthritis. *Vaccines* 9(5).
- Kohler BM, Gunther J, Kaudewitz D, Lorenz HM (2019) Current Therapeutic Options in the Treatment of Rheumatoid Arthritis. *Journal of clinical medicine* 8(7).
- Aletaha D, Smolen JS (2018) Diagnosis and Management of Rheumatoid Arthritis: A Review. *Jama*.320(13): 1360-72.
- Rosenthal KS, Mikecz K, Steiner HL, 3rd, Glant TT, Finnegan A, et al. (2015) Rheumatoid arthritis vaccine therapies: perspectives and lessons from therapeutic ligand epitope antigen presentation system vaccines for models of rheumatoid arthritis. *Expert review of vaccines* 14(6): 891-908.
- Rosenthal KS, Taylor P, Zimmerman DH (2012) J-LEAPS peptide and LEAPS dendritic cell vaccines. *Microbial biotechnology* 5(2): 203-13.
- Zimmerman DH, Taylor P, Bendele A, Carambula R, Duzant Y, et al. (2010) CEL2000: A therapeutic vaccine for rheumatoid arthritis arrests disease development and alters serum cytokine/chemokine patterns in the bovine collagen type II induced arthritis in the DBA mouse model. *International immunopharmacology* 10(4): 412-21.
- Mikecz K, Glant TT, Markovics A, Rosenthal KS, Kurko J, et al. (2017) An epitope-specific DerG-PG70 LEAPS vaccine modulates T cell responses and suppresses arthritis progression in two related murine models of rheumatoid arthritis. *Vaccine* 35(32): 4048-56.
- Markovics A, Ocsko T, Katz RS, Buzas EI, Glant TT, et al. (2016) Immune Recognition of Citrullinated Proteoglycan Aggrecan Epitopes in Mice with ProteoglycanInduced Arthritis and in Patients with Rheumatoid Arthritis. *PLoS one* 11(7): e0160284.

